-
公开(公告)号：US20220396631A1
公开(公告)日：2022-12-15
申请号：US17595637
申请日：2020-05-19
申请人： Lu HUANG , Brian GRANDA , John BLANKENSHIP , Aida ABUJOUB , Tony FLEMING , Haihui LU , Connie HONG , Brian HOLMBERG , Novartis AG
发明人： Brian Walter Granda , John Blankenship , Aida Abujoub , Tony Fleming , Lu Huang , Connie Hong , Brian Holmberg , Haihui Lu
IPC分类号： C07K16/28
摘要： The present disclosure provides multispecific binding molecules that specifically bind to BCMA, a component of a human T-cell receptor complex and either CD2 or a tumor associated antigen, conjugates comprising the multispecific binding molecules, and pharmaceutical compositions comprising the multispecific binding molecules and the conjugates The disclosure further provides methods of using the multispecific binding molecules to treat disease and disorders associated with expression of BCMA. The disclosure yet further provides recombinant host cells engineered to express the multispecific binding molecules and methods of producing the multispecific binding molecules by culturing the host cells under conditions in which the multispecific binding molecules are expressed.
-
公开(公告)号：US20220364055A1
公开(公告)日：2022-11-17
申请号：US17271430
申请日：2019-08-30
申请人： Novartis AG
发明人： Louise Treanor , Michael R. Greene , Jennifer Brogdon , Boris Engels , Glenn Dranoff , Olja Kodrasi , Hyungwook Lim , Akash Sohoni , Elizabeth Dorothy Pratico , Anniesha Hack , Aida Abujoub , Tony Fleming , Lu Huang , Connie Hong , John Blankenship , Brian Holmberg , Chonghui Zhang , Dexiu Bu , Andrew Price , Xu Zhu , Andrew Stein , Attilio Bondanza
IPC分类号： C12N5/0783 , A61K35/17 , A61K31/519 , A61K38/20 , C07K16/28 , C07K14/705
摘要： The invention provides methods of making immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions generated by such methods.
-
公开(公告)号：US20210220404A1
公开(公告)日：2021-07-22
申请号：US17104983
申请日：2020-11-25
申请人： Michael R. Greene , Novartis AG
发明人： Aida Abujoub , John Blankenship , Attilio Bondanza , Jennifer Brogdon , Dexiu Bu , Serena De Vita , Glenn Dranoff , Boris Engels , Tony Fleming , Brian Walter Granda , Michael R. Greene , Carla Patricia Guimaraes , Anniesha Hack , Brian Holmberg , Connie Hong , Lu Huang , Olja Kodrasi , Joni Waiee Lam , Hyungwook Lim , Elizabeth Dorothy Pratico , Andrew Price , Akash Sohoni , Andrew Marc Stein , Louise Treanor , Chonghui Zhang , Xu Zhu
IPC分类号： A61K35/17 , C07K16/28 , A61P35/00 , A61K45/06 , A61K39/395 , C07K14/705 , A61K38/17 , C12N5/0783 , C07K14/725
摘要： The invention provides immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions and methods thereof.
-
公开(公告)号：US11939389B2
公开(公告)日：2024-03-26
申请号：US18170969
申请日：2023-02-17
申请人： Novartis AG
发明人： Aida Abujoub , John Blankenship , Dexiu Bu , Tony Fleming , Brian Holmberg , Connie Hong , Lu Huang , Chonghui Zhang
IPC分类号： C07K16/28 , A61K35/17 , A61P35/00 , C07K14/705 , C07K14/725 , C12N5/0783 , A61K38/00
CPC分类号： C07K16/2878 , A61K35/17 , A61P35/00 , C07K14/7051 , C07K14/70578 , C12N5/0636 , A61K38/00 , C07K2317/565 , C07K2317/622 , C07K2317/732 , C07K2317/76 , C07K2319/02 , C07K2319/03 , C07K2319/30 , C07K2319/33
摘要： The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
-
公开(公告)号：US20230183368A1
公开(公告)日：2023-06-15
申请号：US18170969
申请日：2023-02-17
申请人： Novartis AG
发明人： Aida Abujoub , John Blankenship , Dexiu Bu , Tony Fleming , Brian Holmberg , Connie Hong , Lu Huang , Chonghui Zhang
IPC分类号： C07K16/28 , A61P35/00 , A61K35/17 , C07K14/725 , C07K14/705 , C12N5/0783
CPC分类号： C07K16/2878 , A61P35/00 , A61K35/17 , C07K14/7051 , C07K14/70578 , C12N5/0636 , A61K38/00
摘要： The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
-
公开(公告)号：US11608382B2
公开(公告)日：2023-03-21
申请号：US16439495
申请日：2019-06-12
申请人： Novartis AG
发明人： Aida Abujoub , John Blankenship , Dexiu Bu , Tony Fleming , Brian Holmberg , Connie Hong , Lu Huang , Chonghui Zhang
IPC分类号： C07K16/28 , A61P35/00 , A61K35/17 , C07K14/725 , C07K14/705 , C12N5/0783 , A61K38/00
摘要： The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
-
7.发明申请公开(公告)号：US20220387486A1
公开(公告)日：2022-12-08
申请号：US17246351
申请日：2021-04-30
发明人： Barbara Brannetti , Jennifer Brogdon , Boris Engels , Brian Walter Granda , Lu Huang , Ming Lei , Na Li , Jimin Zhang , Carla Patricia Pinto Guimaraes , Saar Gill , Marco Ruella , Regina M. Young
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.
-
公开(公告)号：US11149076B2
公开(公告)日：2021-10-19
申请号：US16256731
申请日：2019-01-24
发明人： Hans Bitter , Jennifer Mary Bordeaux , Barbara Brannetti , Jennifer Brogdon , Naveen Kumar Dakappagari , Saar Gill , Steven Highfill , Lu Huang , Carl H. June , Ju Young Kim , Ming Lei , Na Li , Andreas Loew , Elena Orlando , Marco Ruella , Thai Tran , Jimin Zhang , Li Zhou
IPC分类号： C07K14/705 , C07K14/725 , C07K16/28 , A61K45/06 , A61K39/00 , A61K38/00
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.
-
9.发明授权公开(公告)号：US10525083B2
公开(公告)日：2020-01-07
申请号：US15727402
申请日：2017-10-06
发明人： Barbara Brannetti , Jennifer Brogdon , Boris Engels , Brian Granda , Lu Huang , Ming Lei , Na Li , Jimin Zhang , Carla Guimaraes
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.
-
10.再颁专利公开(公告)号：USRE49847E1
公开(公告)日：2024-02-27
申请号：US17569389
申请日：2022-01-05
发明人： Barbara Brannetti , Jennifer Brogdon , Boris Engels , Brian Granda , Lu Huang , Ming Lei , Na Li , Jimin Zhang , Carla Guimaraes , Saar Gill , Marco Ruella , Regina M. Young
CPC分类号： A61K35/17 , A61K38/1774 , A61P35/00 , C07K16/2803 , C07K16/2887 , C07K16/2896 , C12N15/85 , A61K2039/505 , C07K2317/24 , C07K2317/31 , C07K2317/622 , C07K2319/03 , C07K2319/33
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.
-
-
-
-
-
-
-
-
-
搜索结果
22 条记录 (耗时 0.037 秒)
